EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study

Joseph Kado iD, Sam Salman iD, Thel K Hla, Stephanie Enkel, Robert Henderson, Robert M Hand iD, Adam Hort, Madhu Page-Sharp, Kevin Batty iD, Brioni R Moore, Julie Bennett, Anneka Anderson und 2 weitere

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.00962-23 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Joseph Kado und 13 weiteren Autor:innen. Beteiligte Einrichtung: Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Rheumatic Fever, Rheumatic Heart Disease. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cure Kids (CK), University of Western Australia (UWA), Telethon Kids Institute (TKI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since 1955, the recommended strategy for rheumatic heart disease (RHD) secondary prophylaxis has been benzathine penicillin G [BPG; 1.2 MU (900 mg)] injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration. The safety, tolerability, and pharmacokinetics of subcutaneous infusions of high-dose BPG were assessed in 24 healthy adult volunteers assigned to receive either 3.6, 7.2, or 10.8 MU (three, six, and nine times the standard dose, respectively) as a single subcutaneous infusion. The delivery of the BPG to the subcutaneous tissue was confirmed with ultrasonography. Safety assessments, pain scores, and penicillin concentrations were measured for 16 weeks post-dose. Subcutaneous infusion of penicillin (SCIP) was generally well tolerated with all participants experiencing transient, mild infusion-site reactions. Prolonged elevated penicillin concentrations were described using a combined zero-order (44 days) and first-order ( t 1/2 = 12 days) absorption pharmacokinetic model. In simulations, time above the conventionally accepted target concentration of 20 ng/mL (0.02 µg/mL) was 57 days for 10.8 MU delivered by subcutaneous infusion every 13 weeks compared with 9 days of every 4-weekly dosing interval for the standard 1.2 MU intramuscular dose (i.e., 63% and 32% of the dosing interval, respectively). High-dose SCIP (BPG) is safe, has acceptable tolerability, and may be suitable for up to 3 monthly dosing intervals for secondary prophylaxis of RHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rheumatic FeverRheumatic Heart DiseaseAdultHumansAnti-Bacterial AgentsInfusions, SubcutaneousPainPenicillin G Benzathine

Stichwörter der Autor:innen

benzathine penicillin Gpopulation pharmacokineticsrheumatic heart diseasesecondary antibiotic prophylaxissubcutaneous infusions

Substanzen

Anti-Bacterial AgentsPenicillin G Benzathine

Autor:innen und Institutionen

  • Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia.
  • Medical School, University of Western Australia, Perth, Western Australia, Australia.
  • Clinical Pharmacology and Toxicology Unit, PathWest, Western Australia, Australia.
  • Department of Infectious Diseases, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  • Medical Imaging Department, Perth Children's Hospital, Nedlands, Western Australia, Australia.
  • Department of Infectious Diseases, Royal Perth Hospital, Perth, Western Australia, Australia.

ORCID-Profile: Joseph Kado, Sam Salman, Robert M Hand, Kevin Batty, Laurens Manning

Förderung

  • Cure Kids (CK)
  • University of Western Australia (UWA)
  • Telethon Kids Institute (TKI)
  • DHAC | National Health and Medical Research Council (NHMRC)

Zitieren

APA

Kado, J., Salman, S., Hla, T. K., Enkel, S., Henderson, R., Hand, R. M., Hort, A., Page-Sharp, M., Batty, K., Moore, B. R., Bennett, J., Anderson, A., Carapetis, J., & Manning, L. (2023). Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00962-23

Vancouver

Kado J, Salman S, Hla TK, Enkel S, Henderson R, Hand RM, et al. Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00962-23

BibTeX
@article{Kado2023,
  author = {Kado, Joseph and Salman, Sam and Hla, Thel K and Enkel, Stephanie and Henderson, Robert and Hand, Robert M and Hort, Adam and Page-Sharp, Madhu and Batty, Kevin and Moore, Brioni R and Bennett, Julie and Anderson, Anneka and Carapetis, Jonathan and Manning, Laurens},
  title = {Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00962-23}
}
Kostenlos starten →